The best biopharma M&A deals
Listen now
Description
At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting.   In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.   From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal.  To learn more about the topics in this episode:   Top 10 smartest deals in biopharma  See omnystudio.com/listener for privacy information.
More Episodes
As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.   While both candidates have pledged to reduce drug costs, their approaches are...
Published 11/01/24
Published 10/28/24
Explore how Turbine AI is revolutionizing drug development by tackling biases in data for more effective cancer treatments.
Published 10/28/24